Broadwood Partners, L.P. Acquires 138,054 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 138,054 shares of the stock in a transaction on Monday, April 7th. The stock was bought at an average price of $15.61 per share, for a total transaction of $2,155,022.94. Following the completion of the purchase, the insider now directly owns 13,332,264 shares in the company, valued at approximately $208,116,641.04. The trade was a 1.05 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Friday, April 4th, Broadwood Partners, L.P. purchased 497,631 shares of STAAR Surgical stock. The shares were bought at an average cost of $15.91 per share, with a total value of $7,917,309.21.
• On Wednesday, April 2nd, Broadwood Partners, L.P. acquired 31,780 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.43 per share, for a total transaction of $553,925.40.
• On Monday, March 31st, Broadwood Partners, L.P. bought 22,189 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.46 per share, with a total value of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. purchased 3,620 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.48 per share, for a total transaction of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was acquired at an average price of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were bought at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The shares were bought at an average cost of $15.49 per share, for a total transaction of $565,880.68.

STAAR Surgical Stock Down 6.5 %

NASDAQ STAA opened at $15.09 on Wednesday. The stock has a market cap of $744.31 million, a PE ratio of -36.80 and a beta of 0.75. The business has a 50 day moving average price of $18.27 and a two-hundred day moving average price of $24.38. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $52.68.

Institutional Investors Weigh In On STAAR Surgical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quarry LP purchased a new position in STAAR Surgical in the 3rd quarter valued at about $50,000. KLP Kapitalforvaltning AS acquired a new position in shares of STAAR Surgical in the fourth quarter worth about $180,000. GAMMA Investing LLC lifted its stake in shares of STAAR Surgical by 4,086.0% in the first quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier’s stock worth $258,000 after acquiring an additional 14,301 shares in the last quarter. Bridgefront Capital LLC boosted its holdings in STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 2,306 shares during the last quarter. Finally, FMR LLC grew its stake in STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock valued at $263,000 after purchasing an additional 3,136 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Jefferies Financial Group lowered STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. Mizuho lowered shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $45.00 to $17.00 in a report on Wednesday, February 12th. Stephens reaffirmed an “equal weight” rating and issued a $17.00 target price on shares of STAAR Surgical in a research report on Tuesday, March 18th. Piper Sandler dropped their price target on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, February 12th. Finally, BTIG Research lowered STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.29.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.